| scholarly article | Q13442814 |
| P2093 | author name string | Meng Chen | |
| Jerry L. Nadler | |||
| Volker Brinkmann | |||
| Runpei Wu | |||
| Zandong Yang | |||
| Kevin R. Lynch | |||
| Justin D. Ellett | |||
| Lawrence B. Fialkow | |||
| P2860 | cites work | Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists | Q29618071 |
| Suppression of autoimmune diabetes by viral IL-10 gene transfer | Q30309447 | ||
| The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice | Q30309929 | ||
| Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite | Q34339041 | ||
| Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols | Q34510369 | ||
| Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. | Q34756546 | ||
| FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity | Q34786932 | ||
| B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice | Q36367653 | ||
| The immune modulator FTY720 targets sphingosine 1-phosphate receptors | Q40736684 | ||
| Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts | Q40845989 | ||
| The identification of myriocin-binding proteins | Q40963836 | ||
| FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression | Q43552626 | ||
| Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. | Q44002416 | ||
| FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. | Q52026935 | ||
| Characterization of pancreatic T lymphocytes associated with beta cell destruction in the non-obese diabetic (NOD) mouse | Q68313988 | ||
| Insulin-dependent diabetes mellitus | Q71046915 | ||
| FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation | Q73004340 | ||
| Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats | Q73376348 | ||
| FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation | Q73423109 | ||
| FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes | Q73531760 | ||
| Prevention of graft vessel disease by combined FTY720/cyclosporine. A treatment in a rat carotid artery transplantation model | Q74052937 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| immunology | Q101929 | ||
| P304 | page(s) | 30-35 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Clinical Immunology | Q15752921 |
| P1476 | title | The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice | |
| The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice☆ | |||
| P478 | volume | 107 |
| Q52578826 | Abnormal islet sphingolipid metabolism in type 1 diabetes. |
| Q30427148 | Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes |
| Q60938765 | Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson's Disease and Diabetes as Well as Potential Therapies? |
| Q23923263 | Disruption of sphingolipid homeostasis by myriocin, a mycotoxin, reduces thymic and splenic T-lymphocyte populations |
| Q36057311 | Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice |
| Q28066824 | Experimental Diabetes Mellitus in Different Animal Models |
| Q38458872 | FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice |
| Q37088194 | From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era. |
| Q48169015 | Local delivery of fingolimod from three-dimensional scaffolds impacts islet graft efficacy and microenvironment in a murine diabetic model |
| Q30428016 | Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells |
| Q28542948 | Prolonging survival of corneal transplantation by selective sphingosine-1-phosphate receptor 1 agonist |
| Q48529387 | Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aβ-induced injury by fingolimod |
| Q30434189 | Regulation of learning and memory by meningeal immunity: a key role for IL-4 |
| Q36861002 | Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism |
| Q44813941 | The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat. |
| Q34274256 | The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 |
| Q24681206 | The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors |
| Q37128721 | The role of sphingosine-1-phosphate and its receptors in asthma |
| Q39021621 | The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases |
| Q57012316 | Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure |
| Q80716400 | [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis] |
Search more.